Century Therapeutics (IPSC) IPO Opens Modestly Lower

Today's IPO for Century Therapeutics (NASDAQ: IPSC) opened for trading at $19.50 after pricing 10,550,000 shares of its common stock at a public offering price of $20.00 per share.

J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler are acting as joint book-running managers for the offering.

Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an opportunity to advance the course of cancer care.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Rubrik (RBRK) Files for 23M Share IPO at $28-$31/sh
• Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock